GlassScriptPhysician profile
Noshaba R Chughtai
NPI 1538458591
$3,973.38
in general payments reported to CMS, 2019-2025
25 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $407 · 2021: $186 · 2022: $263 · 2023: $327 · 2024: $1,301 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747 · Education: $65.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.96 |
| Education | $65.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,364.55 | 2019-2025 | Collagenase Santyl, Renasys Touch, Regranex |
| Glaxosmithkline, LLC. | $599.39 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $467.48 | 2020-2025 | Airsupra, Breztri |
| Pfizer INC. | $183.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.96 | 2022-2025 | |
| Exact Sciences Corporation | $152.76 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $126.21 | 2020-2025 | Zepbound, Mounjaro |
| Amgen INC. | $116.10 | 2024-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $108.63 | 2022-2024 | Ozempic, Rybelsus |
| Tactile Systems Technology INC | $91.90 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Hologic Sales and Service, LLC | $90.47 | 2020-2025 | Thinprep 2000 Processor |
| Mimedx Group, INC. | $73.74 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $58.38 | 2020 | |
| Urgo Medical North America, LLC | $51.57 | 2023-2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.73 | 2024-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $45.71 | 2022 | |
| Merck Sharp & Dohme LLC | $44.91 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $42.05 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.19 | 2021 | |
| Kci USA, INC. | $24.69 | 2019-2022 | |
| Corcept Therapeutics | $23.24 | 2025 | Korlym |
| Amarin Pharma, INC. | $18.28 | 2021 | |
| Sumitomo Pharma America, INC. | $18.19 | 2024 | Gemtesa |
| Vbi Vaccine (Delaware) INC. | $16.00 | 2022 | |
| Aroa Biosurgery Incorporated | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noshaba Chughtai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.